Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Human Stem Cells Institute reports for 3 months of 2023 by RAS

5/2/23 ABIO

IMCB reported for 3 months of 2023 by RAS

5/2/23 GEMA

Human Stem Cells Institute reported 2022 by IFRS

5/2/23 ABIO

Lukoil in 2022 increased oil production by 7.1%

5/2/23 LKOH

Seligdar will develop technology for persistent ores at Kuchus by 2024

5/2/23 SELG

TGC-2 reported for 2022 by IFRS

5/2/23 TGKB

Samaraenergo reported for 2022 by IFRS

5/2/23 SAGO

CVS Health bought Oak Street Health

5/2/23 OSH

Sollers reported for 3 months of 2023 by RAS

5/2/23 SVAV

Bashinformsvyaz reported for 3 months of 2023 by RAS

5/2/23 BISVP